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Summary
Caveolins (CAVs) are essential components of caveolae,
plasma membrane invaginations with reduced fluidity, re-
flecting cholesterol accumulation [1]. CAV proteins bind
cholesterol, and CAV’s ability to move between cellular
compartments helps control intracellular cholesterol fluxes
[1–3]. In humans, CAV1 mutations result in lipodystrophy,
cell transformation, and cancer [4–7]. CAV1 gene-disrupted
mice exhibit cardiovascular diseases, diabetes, cancer,
atherosclerosis, and pulmonary fibrosis [8, 9]. The mecha-
nism or mechanisms underlying these disparate effects are
unknown, but our past work suggested that CAV1 deficiency
might alter metabolism: CAV12/2 mice exhibit impaired
liver regeneration unless supplemented with glucose,
suggesting systemic inefficiencies requiring additional*Correspondence: checa229@yahoo.com (J.C.F.-C.), apols@ub.edu (A.P.)
11These authors contributed equally to this workmetabolic intermediates [10]. Establishing a functional link
between CAV1 and metabolism would provide a unifying
theme to explain these myriad pathologies [11]. Here we
demonstrate that impaired proliferation and low survival
with glucose restriction is a shortcoming of CAV1-deficient
cells caused by impaired mitochondrial function. Without
CAV1, free cholesterol accumulates in mitochondrial
membranes, increasing membrane condensation and
reducing efficiency of the respiratory chain and intrinsic
antioxidant defense. Upon activation of oxidative phosphor-
ylation, this promotes accumulation of reactive oxygen
species, resulting in cell death. We confirm that this mito-
chondrial dysfunction predisposes CAV1-deficient animals
to mitochondrial-related diseases such as steatohepatitis
and neurodegeneration.
Results and Discussion
Establishing a functional link between CAV1 and metabolism
would provide a unifying theme to explain the myriad patholo-
gies resulting from CAV deficiency [11]. Thus, mouse embry-
onic fibroblast cells (MEFs) from wild-type (WT) and CAV12/2
mice [12] were treated with 2-deoxyglucose (2-DG), which
inhibits glycolysis. 2-DG reduced proliferation (Figure 1A)
and dramatically increased cell death of CAV12/2 but not WT
MEFs (Figure 1B). Upon nutrient limitation, cells rely primarily
on mitochondrial oxidative phosphorylation (OXPHOS) [13].
Thus, we analyzed whether the increased apoptosis in
CAV12/2 cells upon glycolysis inhibition might be caused by
increased demands on mitochondria. We treated cells with di-
chloroacetate (DCA) to shift glucose metabolism from lactate
production to OXPHOS [14] (see also Figure S1 available on-
line). DCA preferentially promoted apoptosis in CAV12/2
MEFs (Figure 1C), supporting the hypothesis that lethality is
related to activation of OXPHOS. Because OXPHOS is a major
source of reactive oxygen species (ROS), and because ROSs
are apoptogenic triggers, we quantified cellular ROS levels.
CAV12/2 MEFs had a significantly higher ROS content (Fig-
ure 1D), and DCA treatment enhanced ROS accumulation in
CAV12/2 MEFs. The increased ROS was involved in the
increased apoptosis, because treatment with the antioxidant
Butylated hydroxyanisole (BHA) reduced the proapoptotic
effect of DCA (Figure 1C). These results suggest a mitochon-
drial dysfunction in CAV12/2 cells, which is exacerbated by
stimulation of OXPHOS. This sensitivity is not due to unknown
additional variations in the genetic background and also
occurs in the animal (see also Figures S2 and S3).
How are the CAV12/2 mitochondria altered? Measured by
flow cytometry using MitoTracker FM (data not shown) and
cellular cytochrome C content (Figure 2G and Figure 4E),
mitochondrial content is similar in both cell types. In contrast,
the mitochondrial membrane potential (DJ) was markedly
higher in CAV12/2 cells (Figure 1E). The routine flux control
ratio reflects how close the routine respiration operates to
the respiratory capacity of the electron transport system,
and it was markedly higher in CAV12/2 cells (Figure 1F). We
then purified mitochondria [15] from CAV12/2 and WT murine
liver [16] and quantified function in identical environments.
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Figure 1. Mitochondrial Dysfunction in CAV12/2 Cells
(A) Wild-type (WT; white bars) and CAV12/2mouse embryonic fibroblast (MEF; black bars) were cultured with 2-DG. After 48 hr, cell number was determined
and expressed with respect to the initial number of cells (t0).
(B) Apoptosis, analyzed by flow cytometry via binding of annexin V and staining with propidium iodide, was promoted by 5 mM 2-DG.
(C) Apoptosis was promoted by DCA; some cells were pretreated with the antioxidant BHA.
(D) Levels of ROS in cells incubated during 24 hr with DCA. The results are expressed as the relative H2DCFDA fluorescence with respect to untreated
WT cells.
(E) DJm of CAV12/2 with respect to WT MEF.
(F) Oxygen consumption by WT and CAV12/2 MEF expressed as the routine flux control ratio.
(G) Western blotting analysis of CAV1 (plasma membrane), Rab11 (recycling endosomes), GM130 (Golgi complex), Sec61 (ER), and cytochrome C (Cyt C,
mitochondria) in purifiedWT andCAV12/2mitochondria (M), in homogenates (H), and in a crude fraction that containsmitochondria and associated ER (cM).
(H) Ratios of oxygen consumption in WT (white bars) and CAV12/2 (black bars) mitochondria purified from mice liver. Statistical significances were
determined in at least five independent experiments or ten mice using the Student’s t test; *p < 0.05, **p < 0.01.
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extramitochondrial contamination (Figure 1G). CAV1 was
absent in WT mitochondria, though it was present in a crude
fraction containing mitochondria and associated endoplasmic
reticulum (ER). We determined the respiratory capacity of the
purified mitochondria by examining substrate-driven oxygen
consumption. The acceptor control ratio (ACR) was calculated
to determine the tightness of the coupling between respiration
and ATP production, and the uncoupling control ratio (UCR)
was calculated as the index of oligomycin-inhibited respiration
and FCCP-stimulated respiration. ACR was markedly lower in
CAV12/2 mitochondria, whereas the UCR was unaffected
(Figure 1H). Thus, CAV12/2 mitochondria show reduced flux
between the respiratory chain and the production of energy.
The apparent discrepancy of higher mitochondrial potential
and higher oxygen consumption observed in CAV12/2
cells deserves further analysis, but because the UCR is
unaffected, it is not caused by changes in membrane
permeability.
How might CAV1 loss result in mitochondrial impairment?
CAV1 contributes to intracellular cholesterol homeostasis
[1–3]. CAV1 deficiency might alter mitochondrial cholesterol
levels, which regulate the organelle’s function and apoptotic
susceptibility [15]. CAV12/2 mitochondria had a significant
increase (39%) in free cholesterol (Figure 2A) that could not
account for the presence of other cholesterol-enriched organ-
elles (Figure 1G). This deficiency is generic: a mitochondrialfraction isolated from CAV12/2 MEFs had a similar increase
of 33% (Figure 3A). Mass spectrometry analysis of major lipids
revealed no other significant changes in the total amount of
phospholipids or in the relative enrichment of each phospho-
lipid (Table S1). Thus, only the cholesterol/phospholipid ratio
was altered from 0.79 in WT to 1.00 in CAV12/2 mitochondria.
Mitochondria are cholesterol-poor organelles, and little is
known about regulation of their cholesterol influx or efflux
[17]. Cholesterol likely reaches mitochondria through special-
ized ER domains called mitochondrial-associated membranes
(MAM) [18]. Because it is a MAM resident protein [19] and
transports cholesterol from the ER to the plasma membrane
[20], CAV1 could control MAM cholesterol levels. If so, CAV1
loss would influence steroid synthesis. In steroidogenic cells,
after synthesis in the ER, cholesterol is transported into mito-
chondria, and the P450 side chain cleavage enzyme
(CYP11A1) converts it to pregnenolone, the steroid precursor.
Mitochondrial cholesterol availability is the rate-determining
step in steroid biosynthesis [21], so pregnenolone levels indi-
cate the rate of mitochondrial cholesterol influx. Reduction of
CAV1 levels in steroidogenic F2-CHO cells stably transfected
with CYP11A1 caused a significant increase in pregnenolone
biosynthesis (Figure 2B). Similarly, serum steroid concentra-
tions were significantly higher in CAV12/2 mice (Figure 2C),
confirming at the systemic level that CAV1 deficiency
promotes higher mitochondrial cholesterol influx and thus
increases steroid biosynthesis.
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Figure 2. Cholesterol Accumulation Promotes Dysfunction of CAV12/2 Mitochondria
(A) Free cholesterol in WT (white bars) and CAV12/2 (black bars) mitochondria purified frommice liver. In some experiments, mitochondria were pretreated
with cyclodextrin to extract cholesterol (slashed bars).
(B) Expression of CAV1 in F2-CHO cells was reduced by RNA interference during 48 hr (western blotting of CAV1 is shown on the bottom), and production
of pregnenolone was measured during the next 24 hr.
(C) Pregnenolone, corticosterone, and testosterone levels in the serum of CAV12/2 (black bars) and WT (white bars) mice.
(D) Membrane order analyzed with ANEPPDHQ of WT (white bars), CAV12/2-treated (black bars) and cyclodextrin-treated WT (white bars), and
CAV12/2-purified mitochondria (slashed bars).
(E) Mitochondrial GSH in WT (white bars) and CAV12/2 (black bars) mitochondria purified from mice liver.
(F) Apoptosis promoted by 24 hr of TNFa in untreated WT (white bars) and CAV12/2 MEF (black bars) or in cells treated with GSH-EE.
(G) Cytochrome C (Cyt C) in cytosolic supernatants and homogenates (homog) corresponding to TNFa-treated MEFs.
(H) Purified mitochondria from WT (white bars) and CAV12/2 (slashed bars) were treated with cyclodextrin, and the rates of oxygen consumption
were measured.
(I and J) Purified WT mitochondria (white bars) were enriched with 25% of cholesterol (slashed bars), and membrane condensation (I) and rates of oxygen
consumption (J) were measured.
(K) Influx of a radio-labeled GSH into WT mitochondria untreated (white bars) or enriched with 25% of cholesterol (slashed bars). Statistical significances
were determined in at least five independent experiments or ten mice using the Student’s t test; *p < 0.05, **p < 0.01.
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683In general, cholesterol decreases membrane fluidity, so the
mitochondrial cholesterol increase could alter mitochondrial
membrane properties. We developed a new technique to
measure mitochondrial membrane fluidity and found by di-4-
ANEPPDHQ that purified CAV1 2/2 mitochondria had
increasedmembranecondensation (Figure2DandseeSupple-
mental Experimental Procedures). Reducedmembrane fluidity
impairs import of glutathione into the mitochondria (mGSH)
[15]. GSH is a key antioxidant that modulates the oxidative
state of the cell and ultimately apoptosis [22]. Indeed, purified
CAV12/2 hepatic mitochondria had a 28% reduction in mGSH
content (Figure 2E). A mitochondrial fraction isolated from
CAV12/2 MEFs also showed a reduction of 59% (Figure 3B).
Decreased mGSH partially explains the ROS accumulation in
CAV12/2 cells. Mitochondrial GSH reduction predisposes cells
to apoptosis [15, 22], and indeed CAV12/2 MEFs displayed
significantly higher apoptosiswhen challengedwith TNFa (Fig-
ure 2F). The increased apoptosis was confirmed by measuring
cytochrome C release into the cytosol (Figure 2G). Using
cell-permeable GSH ethyl ester (GSH-EE) to increase mGSH
levels eliminated the difference in apoptotic sensitivity
between WT and CAV12/2 fibroblasts (Figure 2F).
These data thus support the hypothesis that CAV1 defi-
ciency promotes cholesterol accumulation in mitochondria,
reducingmembrane fluidity and causing organelle dysfunctionby (1) reducing respiratory chain efficiency and increasing
ROS levels and (2) reducing uptake of mGSH and thus
mitochondrial antioxidant defense. To directly test choles-
terol’s role, we treated purified CAV12/2 mitochondria with
beta-cyclodextrin to extract cholesterol. This restored the
cholesterol/phospholipid ratio of CAV12/2 mitochondria to
the WT levels without affecting the amount of phospholipids
(4.30 6 1.15 ng cholesterol/mg protein and 6.06 6 0.76 nmol
Pi/mg protein; Figure 2A). Critically, these CAV12/2 mitochon-
dria treated with cyclodextrin had reduced membrane order,
as shown by di-4-ANEPPDHQ (Figure 2D), and their ACR index
recovered toWTmitochondria levels (Figure 2H). Further, their
susceptibility to mitochondrial toxins was reversed (Figure 4I).
Conversely, when purified WT mitochondria were loaded with
an additional 25% of cholesterol, they demonstrated
increased membrane order (Figure 2I), reduced ACR index
(Figure 2J), and reduced entry of mGSH (Figure 2K). Re-
expression by retroviral infection of CAV1 in CAV12/2 MEF
[23] recovered mitochondrial cholesterol and mGSH levels
(Figures 3A and 3B), reduced the routine flux control ratio,
especially after OXPHOS activation by DCA (Figure 3C), and
decreased the oxidative stress caused by DCA as measured
by oxidation of Dihydroethidium (DHE) (Figure 3D). In
summary, dysfunction in the CAV12/2 mitochondria largely
results from increased mitochondrial cholesterol.
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Figure 3. Reexpression of CAV1 Recovers Mitochondrial Function
(A and B) Free cholesterol and GSH in mitochondria purified from WT (white bars), CAV12/2 (black bars), CAV12/2-reconstituted MEFs (slashed bars),
and CAV12/2 MEF infected with an empty vector (black bars). CAV1 levels are shown by western blotting.
(C) Routine flux control ratio in untreated MEFs and in cells incubated with DCA for 5 hr.
(D) Oxidative stress caused by mitochondrial function in MEFs. Results are expressed as the ratio between the fluorescence intensity of DHE after treating
the cells with DCA for 5 hr with respect to the initial intensity. Statistical significances were determined in at least five independent experiments using the
Student’s t test; *p < 0.05, **p < 0.01.
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animals sensitive to diseases involvingmitochondrial malfunc-
tion. Because cholesterol loading of mitochondria is known to
sensitize the liver to steatohepatitis [15], CAV12/2mice should
be particularly sensitive to this disease. We treated mice with
the agonistic anti-Fas antibody Jo2. Injury was minimal in
WT liver, but in CAV12/2 mice Jo2 caused appearance of
serum transaminases reflecting hepatic damage (Figure 4A).
Steatohepatitis progression was shown by hematoxiline-eosin
staining and inflammatory cell infiltration of liver sections
(Figures 4B and 4C). The increased susceptibility of CAV12/2
hepatocytes to Jo2 was reproduced in isolated primary
hepatocytes (Figures 4D–4F). Importantly, increasing cellular
GSH levels by the cell-permeable GSH ethyl ester rescued
CAV12/2 hepatocytes from Jo2-induced cell death (Figure 4F).
Mitochondrial impairment and oxidative stress contribute to
neuronal death in multiple forms of neurodegeneration [24],
and CAV12/2 brain mitochondria also have increased choles-
terol levels and reduced mGSH (Figures 4G and 4H). To test
whether CAV1 loss also sensitized these mitochondria to
typical neurodegenerative insults, we incubated mitochondria
with oligomeric human recombinant Ab1-42 (the amyloid beta
peptide [Ab] characteristic of Alzheimer’s disease and a potent
mitochondrial toxin [25]). CAV12/2 brain mitochondria had
higher ROS generation (Figure 4I) and enhanced cytochrome
C release (data not shown). This effect was reversed by ex-
tractingmitochondrial cholesterol with cyclodextrin (Figure 4I).
Finally, we tested for mitochondrial dysfunction in the intact
brain by injecting 3-Nitropropionic acid (3-NP). This is a mito-
chondrial toxin used extensively as a model of Huntington’s
disease; its toxicity is associated with oxidative stress [26].
3-NP was injected in the striatum of WT and CAV12/2 mice,
and degenerating cells were visualized 24 hr later. In the
CAV12/2 striatum, we found a much larger lesion (Figure 4J;
volume quantified in serial sections), and by staining with
TUNEL (Figure 4K), we calculated twice the apoptotic neurons
per lesion (62.3 3 103 6 7.6 3 103 in WT and 133 3 103 6
13.5 3 103 in CAV12/2; **p < 0.01).
In summary, CAV1 deficiency impairs mitochondria by
promoting an increased influx and accumulation of free
cholesterol in mitochondrial membranes. This increases
membrane condensation, decreasing efficiency of the respira-
tory chain and the intrinsic antioxidant defense. Upon activa-
tion of OXPHOS, the combination of these factors promotesaccumulation of ROS, resulting in cell death. Although we
only investigated the effect of the mitochondrial failure caused
by CAV1 deficiency in liver, brain, and fibroblasts, naturally
occurring CAV1 deficiencies in humans cause disease in other
tissues as well. The precise contribution of the mitochondrial
dysfunction in the appearance and/or progression of the
pathologies attributed to the loss of CAV should now be
addressed in each specific case. In this respect, we have
confirmed organismal vulnerability to mitochondrial perturba-
tions occurring during progression of steatohepatitis and
neurodegeneration. In a physiological context, cells are
continuously exposed to changes in the balance between
aerobic glycolysis and mitochondrial oxidative metabolism,
so our findings more generally suggest that CAV deficiency
will progressively result in mitochondrial failure, sustained
oxidative stress, and apoptosis, casually contributing to
disease pathogenesis.
Experimental Procedures
Reagents and Antibodies
BHA (B1253), GSH-EE (G1404), DCA (347795), 2-DG (31060, Fluka), insulin
(I9278), EGF (E1557), PDGF (P4056), collagenase type IV (C5138), glucose
(8270), fatty acids (L9655), and 3-NP (N5636) were from Sigma. Jo2
(554254) was from PharMingen, Hoechst-33258, Deep Red MitoTracker
(M22426), MitoTracker green FM (M-7514), and DHE (D11347) were from
Molecular Probes, Trypsin/EDTA was from Life Technologies, TNFa
(300-01A) was from PeproTech (Bionova), monoclonal anti-cytochrome
C (6H2B4) was from BD PharMingen, anti-smac/DIABLO was from Calbio-
chem, anti-GFP (ab290) was from Abcam, and anti-CAV1 (C13630) and
anti-actin were from Transduction Labs.
Cells and Animals
MEFs [12] were grown in Dulbecco’s modified Eagle’s medium supple-
mented with 5% fetal bovine serum, L-glutamine (2 mM), penicillin
(50 U/ml), and streptomycin sulfate (50 mg/ml) (Biological Industries).
F2-CHO, 3T3L1 cells, CAV12/2-reconstituted MEFs, and CAV12/2 MEF
stably transfected with the empty vector were obtained and cultured as
described [23, 27, 28]. CAV12/2 and WT mice [16] were kept under
a controlled humidity and lighting schedule with a 12 hr dark period. All
animals received human care in compliance with institutional guidelines
regulated by the European Community. A complete description of the
experimental procedures can be found in the Supplemental Experimental
Procedures.
Statistical Analysis
The statistical significance of differences was determined using the
Student’s t test; *p < 0.05, **p < 0.01.
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Figure 4. Dysfunction of CAV12/2 Mitochondria
Enhances Pathogenesis
(A–C) To model steatohepatitis, we treated WT
(white bars) and CAV12/2 (black bars) mice with
Jo2. Liver damage was evaluated 24 hr later by
appearance of transaminases in serum (AST and
ALT). Inflammation was visualized in liver
sections of WT (left) and CAV12/2 (right) mice
with hematoxiline/eosin and myeloperoxidase
staining.
(D and E) WT and CAV12/2 primary hepatocytes
were treated with Jo2 for 24 hr. Apoptosis in WT
(left) and CAV12/2 (right) hepatocytes was visual-
ized with a Hoechst staining (D) and released
cytochrome C (CytC) into the cytosol quantified
by western blot (E).
(F) MTT cell viability assay of WT and CAV12/2
hepatocytes treated with Jo2 or with Jo2/
GSH-EE.
(G andH) Free cholesterol andmGSH inWT (white
bars) and CAV12/2 (black bars) purified brain
mitochondria.
(I) ROS generation inWT (white bars) andCAV12/2
(black bars) purified brain mitochondria (some
treatedwith cyclodextrin, slashedbars) incubated
with Ab1-42.
(J and K) 3-NP was injected in the striatum of WT
and CAV12/2 mice, and the volume of the lesion
measured 24 hr later in serial Fluoro-Jade-stained
sections and apoptotic nucleus were visualized in
TUNEL-stained sections (K) of WT (left) and
CAV12/2 (right) striatum. Statistical significances
were determined in at least five independent
experiments or ten mice using the Student’s
t test; *p < 0.05, **p < 0.01.
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